Ross Maltz
Biochemistry, Genetics and Molecular Biology · The Ohio State University
Publications
101
Citations
637
Est. group size
~4
Recurring co-author estimate
Active years
34
Publishing since 1993
Ross Maltz studies inflammatory bowel disease (IBD, including Crohn's disease and ulcerative colitis) in children and young adults, focusing on treatment approaches such as biologic drugs (e.g., infliximab, adalimumab, ustekinumab) and their biosimilar alternatives. His work also examines healthcare access, drug approval policies, and outcomes for young patients with IBD, often drawing on multicenter patient registries and survey data. This research is aimed at improving clinical care and advocacy for pediatric and young adult patients with digestive tract inflammatory conditions.
Publication output has grown steadily over the last decade, rising from about 1 paper in 2017 to around 13-20 per year by 2023-2025.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- P0937 Antibiotic duration is not associated with healing of perianal fistulising complications of Crohn’s disease
Journal of Crohn s and Colitis · 2026
- CLINICAL OUTCOMES OF ADALIMUMAB NONMEDICAL SWITCHES IN PEDIATRIC AND YOUNG ADULT PATIENTS WITH INFLAMMATORY BOWEL DISEASE
Inflammatory Bowel Diseases · 2026
- EARLY PROACTIVE THERAPEUTIC DRUG MONITORING OF INFLIXIMAB ACCELERATES TIME TO REMISSION IN CHILDREN WITH INFLAMMATORY BOWEL DISEASE
Inflammatory Bowel Diseases · 2026
- Inflammatory Bowel Disease Following Allogeneic Hematopoietic Cell Transplant for Sickle Cell Disease
Pediatric Blood & Cancer · 2025
- Children With Inflammatory Bowel Diseases are Disadvantaged by Current Drug Approval Policies: A Call for Urgent Change
Crohn s & Colitis 360 · 2025
- Young Adults with Inflammatory Bowel Disease in the US Experience Gaps in Healthcare Access and Financial Stress: Additional Findings from a Recent Survey by the Crohn’s & Colitis Foundation
Crohn s & Colitis 360 · 2025
- Infliximab Biosimilar Utilization in a Large Pediatric Learning Health System
Children · 2025
- Tu1014: YOUNG ADULTS WITH IBD IN THE U.S. EXPERIENCE GAPS IN HEALTHCARE ACCESS AND FINANCIAL STRESS : ADDITIONAL FINDINGS FROM A RECENT SURVEY BY THE CROHN’S & COLITIS FOUNDATION
Gastroenterology · 2025
- Multicenter study of continuing ustekinumab after intravenous induction reactions in pediatric Crohn's disease
JPGN Reports · 2025
- Healthcare Access for Patients With Inflammatory Bowel Disease in the United States: A Survey by the Crohn’s & Colitis Foundation
Inflammatory Bowel Diseases · 2024
- Biosimilars for Pediatric Patients With Inflammatory Bowel Disease
Journal of Pediatric Gastroenterology and Nutrition · 2023
- Advocacy for Pediatric Patients with IBD
2023
- Utilization of Antitumor Necrosis Factor Biologics in Very Early Onset Inflammatory Bowel Disease
Journal of Pediatric Gastroenterology and Nutrition · 2022
- There Is No Substitute for Effective Education About Biosimilars
Crohn s & Colitis 360 · 2021
- <i>Natural History of </i> Very Early Onset Inflammatory Bowel Disease <i>in North America: A Retrospective Cohort Study</i>
Inflammatory Bowel Diseases · 2020
- Gastroenterology×24
- Journal of Pediatric Gastroenterology and Nutrition×23
- Inflammatory Bowel Diseases×18
- JPGN Reports×5
- Crohn s & Colitis 360×4
- Hilary K. Michel
Biochemistry, Genetics and Molecular Biology · The Ohio State University
- Brendan Boyle
Biochemistry, Genetics and Molecular Biology · The Ohio State University
- Jennifer L. Dotson
Biochemistry, Genetics and Molecular Biology · The Ohio State University
- Antonia Boger-May
Biochemistry, Genetics and Molecular Biology · Indiana University
- Chang Kyun Lee
Biochemistry, Genetics and Molecular Biology · Purdue University West Lafayette
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile